Alternative Component Pathway Inhibition with Ibtacopan for the Treatment of C3 Glomerulopathy - Study Design of the APPEAR -C3G Trial

Recorded On: 10/03/2022

Alternative Component Pathway Inhibition with Ibtacopan for the Treatment of C3 Glomerulopathy - Study Design of the APPEAR -C3G Trial

Key:

Complete
Failed
Available
Locked
Alternative Component Pathway Inhibition with Ibtacopan for the Treatment of C3 Glomerulopathy - Study Design of the APPEAR -C3G Trial
Open to view video.
Open to view video.